Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: MDxHealth, Bionano Genomics, Devyser, Qlucore, Gradientech

NEW YORK – MDxHealth this week reported that its revenues for the first half of 2023 more than doubled to $31.4 million from $13.0 million a year ago. For the second quarter, the company, which has offices in Irvine, California, and Herstal, Belgium, posted $16.7 million in revenues compared to $6.9 million a year ago. H1 2023 revenues were comprised of $14.0 million from the Oncotype DX GPS prostate cancer testing business, $12.4 million from the Confirm mdx business, $3.7 million from the Resolve mdx business, and the rest from the Select MDx and other businesses. MDxHealth had a net loss of $22.3 million, or $.08 per share, in Q2 2023 compared to a net loss of $18.1 million, or $.12 per share, a year ago. The firm attributed the wider loss in the recently completed quarter mainly to increased expenses. It had $39.5 million in cash and cash equivalents as of June 30.

Bionano Genomics has regained compliance with Nasdaq's minimum bid price requirement this week. The company said it received a notification letter from the Nasdaq Stock Market, stating the closing bid price of the company common stock has been at $1.00 per share or greater for the last 10 consecutive business days, from Aug. 7 to Aug. 18. Bionano was previously notified by Nasdaq in May that the company was not in compliance with the minimum bid price requirement.

Devyser Diagnostics, a developer of genetic testing products for the hereditary disease, oncology, and transplant fields, this week said that its second quarter sales grew 22 percent to SEK 37.7 million ($3.4 million) from SEK 30.9 million a year ago. On a currency neutral basis, sales were up 13 percent year over year, the Swedish firm said. It had a total comprehensive loss of SEK 13.5 million, or SEK .90 per share, for the recently completed quarter compared to a total comprehensive loss of SEK 14 million, or SEK .90 per share, a year ago. Devyser had SEK 303.0 million in cash and cash equivalents at the end of Q2 2023.

Qlucore said this week that it has won a grant worth SEK 200,000 ($18,275) from the Swedish Agency for Innovation Systems — known as Vinnova — through the Medtech4Health program to enhance data security as the company builds its Qlucore Diagnostics business unit. The firm said that it is on track for Qlucore Diagnostics to have a CE-marked in vitro diagnostics device by 2025.

Gradientech announced this week that its second quarter earnings were SEK 1.1 million ($103,845) compared to SEK 4,000 in the year-ago period, attributed to sales of the firm's QuickMIC instrument and consumables. In July, the QuickMIC system was granted breakthrough device designation from the US Food and Drug Administration. Gradientech posted a net loss of SEK 16.8 million, or SEK .95 per share, compared to a net loss of SEK 17.7 million, or SEK 1.11 per share, in Q2 2022. The firm ended the quarter with approximately SEK 40 million in cash and cash equivalents.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.